Realizing the promise.
We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.

Aoife Brennan, MB, BCh, BAO, MRCPI
Aoife Brennan, MB, BCh, BAO, MRCPI
Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.
Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until it’s acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.
Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.

Gregg Beloff
Gregg Beloff

Richard Riese, MD, PhD
Richard Riese, MD, PhD

DAVID HAVA, PHD
David Hava, PhD

Adam Thomas
Adam Thomas

Antoine Awad
Antoine Awad

Caroline B. Kurtz, PhD
Caroline B. Kurtz, PhD

Daniel Rosan
Daniel Rosan
Dan brings broad expertise in strategy, long range planning, valuation, corporate development, capital allocation, and portfolio management. He previously spent six years at Biogen in roles of increasing responsibility in Finance and Research & Development and supported significant corporate transactions. Most recently he directed Biogen’s R&D Resource & Performance Management team, which provided project management for assets from pre-clinical through clinical proof of concept; drove the integration of external assets and companies into Biogen’s R&D organization; and led R&D business & portfolio planning.
Earlier in his career, Dan was a management consultant with Frankel Group (acquired by Huron Life Sciences in 2014), a boutique firm serving biotechnology companies and investors. He began his career as a public health advocate and community organizer. Dan holds a BA in History from Vassar College and an MBA from Harvard Business School.

Michael Slater
Michael Slater
